{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    35,
    36,
    37,
    38,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ibrutinib",
        "type": {
          "id": "8766aa1e-ea42-4450-a8ac-b15a203225cc",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "1b76b2c2-3a36-4912-adde-928ba158d4a6",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "First-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton’s tyrosine kinase (BTK).",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "046254a0-b9bc-4232-ad14-8bc211a1fe1e",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "3cbc11a7-40f7-4eaf-b7a3-056ed7c43bf1",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for ibrutinib.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Bendamustine hydrochloride",
        "type": {
          "id": "f90ef055-9dc4-4518-b5b8-abbcbb894227",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "f6259a92-7367-4097-9994-da4a9863c930",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Antineoplastic alkylating agent used in combination with rituximab (BR regimen).",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Rituximab",
        "type": {
          "id": "92347083-2f8a-401e-825e-1348a1800b1c",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "2a533e42-740c-48ae-82b6-7e97abad6685",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "CD20-directed cytolytic antibody used in induction and maintenance phases.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Antimicrobial prophylaxis",
        "type": {
          "id": "64372ea0-cfa9-4975-b70e-21cdd4f23ec9",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "94995f25-efca-4c13-a564-124bda75e035",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and should be considered for subjects at increased risk for opportunistic infections.",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Anti-hormonal therapy",
        "type": {
          "id": "0d70b71e-93a1-463a-b66b-3e5f79503f38",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4600279b-8d64-40c4-96e8-0d23a04eed98",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted after discussion with the sponsor’s medical monitor."
      },
      {
        "id": "int_7",
        "name": "Warfarin",
        "type": {
          "id": "937f4ec5-dbe1-4bc5-b6e0-4176858e6f25",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ccc65d58-07a0-4bde-aa07-3d5870b15073",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited; other vitamin K antagonists are also prohibited."
      },
      {
        "id": "int_8",
        "name": "Fish oil and Vitamin E",
        "type": {
          "id": "5f145c29-65f4-447a-bf67-ebbb0e6bef34",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "11953b1c-a5c0-41ab-b1c6-fb201a897db8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Supplements that should be avoided due to bleeding risk."
      },
      {
        "id": "int_9",
        "name": "Strong or moderate CYP3A inhibitors",
        "type": {
          "id": "fb68c1ab-f3ac-44df-83df-c43c71c9b3b6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "7629b273-3beb-4247-a642-0554446cd7a6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Should be avoided; if required, ibrutinib dose must be reduced or withheld."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ibrutinib capsules",
        "administrableDoseForm": {
          "id": "63f0ea42-32b2-42b5-8514-40972620828b",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "394b7fb4-4f4f-4198-bc10-6dd5ddf81daa",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "94722fd7-27ec-4bc3-aafd-38d99118fe1d",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "140 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development / Pharmacyclics LLC"
      },
      {
        "id": "prod_2",
        "name": "Bendamustine hydrochloride",
        "administrableDoseForm": {
          "id": "bce55d53-e1b4-4667-885f-4d063bb720cb",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "16879fa7-8bce-4887-b1a5-0d389c92bdab",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "c4e55173-8931-4324-9264-c93530652307",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      },
      {
        "id": "prod_3",
        "name": "Rituximab",
        "administrableDoseForm": {
          "id": "a77186b8-8a73-4491-83e2-9dd5d4ca108a",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "451c74fa-7792-497e-ba59-548402272524",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "c31878ce-b524-4868-a38a-f8d9fdcb1ad7",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_3"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Ibrutinib 560 mg daily",
        "instanceType": "Administration",
        "dose": "560 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Daily and continuously until disease progression or unacceptable toxicity"
      },
      {
        "id": "admin_2",
        "name": "Bendamustine 90 mg/m2",
        "instanceType": "Administration",
        "dose": "90 mg/m2",
        "doseFrequency": "Days 1 and 2 of each 28-day cycle",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Maximum of 6 cycles"
      },
      {
        "id": "admin_3",
        "name": "Rituximab Induction",
        "instanceType": "Administration",
        "dose": "375 mg/m2",
        "doseFrequency": "Day 1 of each 28-day cycle",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Cycles 1 to 6"
      },
      {
        "id": "admin_4",
        "name": "Rituximab Maintenance",
        "instanceType": "Administration",
        "dose": "375 mg/m2",
        "doseFrequency": "Day 1 of every second cycle (even cycles)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Maximum of 12 additional doses (up to Cycle 30)"
      },
      {
        "id": "admin_5",
        "name": "Ibrutinib Dose Reduction (Strong CYP3A Inhibitor)",
        "instanceType": "Administration",
        "dose": "140 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Duration of strong CYP3A inhibitor use"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Ibrutinib",
        "instanceType": "Substance",
        "description": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one"
      },
      {
        "id": "sub_2",
        "name": "Bendamustine hydrochloride",
        "instanceType": "Substance",
        "description": "Mechlorethamine derivative"
      },
      {
        "id": "sub_3",
        "name": "Rituximab",
        "instanceType": "Substance",
        "description": "Monoclonal antibody"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 9,
      "productCount": 3,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ibrutinib",
        "role": "Investigational Product",
        "description": "First-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton’s tyrosine kinase (BTK)."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules for ibrutinib."
      },
      {
        "name": "Bendamustine hydrochloride",
        "role": "Background Therapy",
        "description": "Antineoplastic alkylating agent used in combination with rituximab (BR regimen)."
      },
      {
        "name": "Rituximab",
        "role": "Background Therapy",
        "description": "CD20-directed cytolytic antibody used in induction and maintenance phases."
      },
      {
        "name": "Antimicrobial prophylaxis",
        "role": "Concomitant Medication",
        "description": "Permitted and should be considered for subjects at increased risk for opportunistic infections."
      },
      {
        "name": "Anti-hormonal therapy",
        "role": "Concomitant Medication",
        "description": "Permitted after discussion with the sponsor’s medical monitor."
      },
      {
        "name": "Warfarin",
        "role": "Concomitant Medication",
        "description": "Prohibited; other vitamin K antagonists are also prohibited."
      },
      {
        "name": "Fish oil and Vitamin E",
        "role": "Concomitant Medication",
        "description": "Supplements that should be avoided due to bleeding risk."
      },
      {
        "name": "Strong or moderate CYP3A inhibitors",
        "role": "Concomitant Medication",
        "description": "Should be avoided; if required, ibrutinib dose must be reduced or withheld."
      }
    ],
    "products": [
      {
        "name": "Ibrutinib capsules",
        "doseForm": "Capsule",
        "strength": "140 mg",
        "manufacturer": "Janssen Research & Development / Pharmacyclics LLC"
      },
      {
        "name": "Bendamustine hydrochloride",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      },
      {
        "name": "Rituximab",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Ibrutinib",
        "description": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one"
      },
      {
        "name": "Bendamustine hydrochloride",
        "description": "Mechlorethamine derivative"
      },
      {
        "name": "Rituximab",
        "description": "Monoclonal antibody"
      }
    ],
    "administrations": [
      {
        "name": "Ibrutinib 560 mg daily",
        "dose": "560 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Daily and continuously until disease progression or unacceptable toxicity"
      },
      {
        "name": "Bendamustine 90 mg/m2",
        "dose": "90 mg/m2",
        "frequency": "Days 1 and 2 of each 28-day cycle",
        "route": "Intravenous",
        "duration": "Maximum of 6 cycles"
      },
      {
        "name": "Rituximab Induction",
        "dose": "375 mg/m2",
        "frequency": "Day 1 of each 28-day cycle",
        "route": "Intravenous",
        "duration": "Cycles 1 to 6"
      },
      {
        "name": "Rituximab Maintenance",
        "dose": "375 mg/m2",
        "frequency": "Day 1 of every second cycle (even cycles)",
        "route": "Intravenous",
        "duration": "Maximum of 12 additional doses (up to Cycle 30)"
      },
      {
        "name": "Ibrutinib Dose Reduction (Strong CYP3A Inhibitor)",
        "dose": "140 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Duration of strong CYP3A inhibitor use"
      }
    ],
    "devices": []
  }
}